Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human CD14+ monocytes from volunteers before and after a 3 hours, 24 hours and 120 hours-period of methotrexate intake. METOMAC trial

ABSTRACT: Arthritis patients receive a weekly low-dose of Methotrexate (MTX) as a first-line disease modifying anti-rheumatic drug. Following low-dose administration, MTX typically reaches peak plasma concentrations after 1-2 hours, and almost completely disappears from the circulation by 24 hours. However, the kinetics of the anti-inflammatory action of MTX in monocytes after the initial dose is unknown.To address this issue, we carried out a phase I clinical trial (METOMAC) in which peripheral blood from 6 healthy donors receiving a single dose of MTX was analyzed at distinct time points after drug intake (3 hours, 24 hours, 120 hours). RNA-seq on monocytes isolated at the distinct timepoints was determined.

ORGANISM(S): Homo sapiens

PROVIDER: GSE289101 | GEO | 2026/04/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Human CD14+ monocytes from early inflammatory arthritis patients before and after a 5day-and 30day-period of methotrexate treatment

Project description:Methotrexate (MTX) continues to be the anchor drug for patients with rheumatoid arthritis and psoriatic arthritis (RA and PsA) both as monotherapy as well as in combination with other drugs because of its efficacy, safety, low relative cost and the possibility of individualizing dose and method of administration. Following low-dose administration, MTX typically reaches peak plasma concentrations after 1-2 h, and almost completely disappears from the circulation by 24 h. Cellular uptake of MTX is mediated by the Reduced Folate Carrier. Once internalize, MTX is converted into MTX-polyglutamates (MTX-PG), a process that is catalyzed by folylpolyglutamate synthase (FPGS), which sequentially adds glutamic acid residues to MTX, and is one of the critical factors for the therapeutic action of MTX. We carried out a clinical observational study to evaluate the influence of MTX-PG levels on the molecular inflammatory state of monocytes from arthritis patients and relate to the clinical efficacy of MTX.

2026-04-01 | GSE279719 | GEO

Tet-ZFP36L1 in 6 hours and 24 hours

Project description:Tet-ZFP36L1 in 6 hours and 24 hours

| PRJNA561514 | ENA

Human peripheral blood cells (PB): Effect of Tocilizumab/MRA compared to methotrexate(MTX) treatments on rheumatoid arthritis(RA) patients.

Project description:This microarray study was conducted along with SATORI study, the clinical trial evaluated 125 patients with active RA with an inadequate response to low dose of MTX. Patients were allocated to receive either Tocilizumab(TCZ) 8 mg/kg every 4 weeks (TCZ group) or MTX 8 mg/week (MTX/control group) for 24 weeks. Gene expression profiles (GEP) of 112 patients - 54 patients from TCZ group and 58 patients from MTX group - were obtained in this study.

2014-01-29 | GSE35455 | GEO

Single-Cell RNA Sequencing to Decipher the Immunogenicity of ChAdOx1 nCoV-19/AZD1222 and mRNA-1273 Vaccines in Patients with Autoimmune Rheumatic Diseases

Project description:Objectives: To investigate the differences in efficacy and safety between the vector vaccine ChAdOx1 nCoV-19/AZD1222 (Oxford-AstraZeneca) and mRNA-based vaccine mRNA-1273 (Moderna), and evaluate the impact of anti-rheumatic medications on immunogenicity in patients with autoimmune rheumatic diseases (AIRD). Methods: From September 16 to November 15, 2021, we consecutively enrolled participants aged≥20 years with AIRD who received COVID-19 vaccination. The level of serum IgG antibodies to the SARS-Cov-2 receptor-binding domain on the spike protein S1 subunit was quantified by electrochemiluminescence immunoassay at 4-6 weeks after vaccination. The immunogenicity and adverse reactions between ChAdOx1 nCov-19/AZD1222 and mRNA-1273 were compared. Results: Of the 243 rheumatic disease patients who received COVID-19 vaccines, 113 and 130 were immunized with AZD1222 and mRNA-1273, respectively. The anti-SARS-CoV-2 IgG seropositivity rate was 78.8% (89/113) for AZD1222 and 83.1% (108/130) for mRNA-1273. The level of anti-SARS-Cov-2 IgG was higher in patients who received mRNA-1273 than in those who received AZD1222. Prednisolone-equivalent dose >5 mg/day, methotrexate (MTX), non-anti-tumor necrosis factor (TNF)-a biologics, and Janus kinase (JAK) inhibitor use were associated with inferior immunogenicity. All reported adverse reactions were minor. More localized pain at the injection site and less fever and chills were observed in patients receiving mRNA-1273 compared with those receiving AZD1222. Rheumatic disease activities after vaccination remained stable in most patients. Conclusions: mRNA-1273 and AZD1222 vaccines exhibited differential immunogenicity and adverse reaction profiles. Our study findings support temporary discontinuation of daily prednisolone dose >5 mg, MTX, non-anti-TNF-a biologics, or JAK inhibitors after COVID-19 vaccination.

2022-05-19 | GSE203081 | GEO

Restoration of CD56dim NK Cells by Methotrexate Contributes to the Treatment of Juvenile Idiopathic Arthritis

Project description:Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. To elucidate the mechanism of methotrexate (MTX) treatment-induced JIA clinical remission, we conducted single-cell RNA sequencing (scRNA-seq) analysis of peripheral blood mononuclear cells (PBMCs) obtained from a female JIA patient before and after MTX treatment. Besides, we integrated our data with public bulk RNA-seq data. We found that the proportion of the CD56dim NK subsets was restored after MTX treatment, suggesting that CD56dim NK subsets are mainly involved in MTX treatment-induced JIA clinical remission. Differential expression analysis showed that the NK cell-mediated cytotoxicity pathway was riched in CD56dim NK subsets. Furthermore, bulk RNA-seq results showed that MTX-treated NK-92 cell lines were also enriched for NK cell-mediated cytotoxicity pathways. Our data highlight the importance of CD56dim NK subsets in MTX treatment-induced JIA clinical remission.

2025-12-31 | GSE268374 | GEO

AGS infected with H. pylori for 24 hours

Project description:AGS infected with H. pylori for 24 hours

| PRJNA1190116 | ENA

Methotrexate activates aspects of inflammation in EA.hy 926 cells

Project description:Methotrexate (MTX) is an anti-folate drug used to treat inflammatory diseases such as rheumatoid arthritis. The changes induced by MTX were profiled within EA.hy 926 cells grown in normal (Hi) and low (Lo) folate. Several inflammatory genes were up regulated and several mitosis related genes were down regulated. Hi and Lo cells were grown to confluence and maintained in fresh medium for 24 hours prior to treatment with 0.5uM MTX for 48 hours.

2012-09-30 | E-GEOD-32008 | biostudies-arrayexpress

Effect on gene expresssion in HeLa cells treated for 8 hours and 24 hours with 1 micromolar CTT25136

Project description:To investigate the effect the small molecule CTT251236 has on gene expression in HeLa cells following 8 hours and 24 hours of treatment We performed gene expression profiling analysis using data obtained from RNA-seq of solvent treated cells (control) and cells treated for 8 hours and for 24 hours. Each condition was performed in triplicate.

2022-05-12 | GSE202513 | GEO

Nitrosopumilus maritimus SCM1: exponential phase control vs. 24 hours starvation vs. 24 hours recovery after starvation

Project description:Transcriptional profiling of marine ammonia oxidizing archaea Nitrosopumilus maritimus cells comparing exponential phase control cells with cells under 24 hours starvation and with cells under recovery after 24 hours starvation. Goal was to determine the effects of global transcriptional responses of N. maritimus cells under ammonia starvation and recovery conditions.

2017-11-01 | GSE103848 | GEO

microRNA expression in primary murine Alveolar type II cells under Normoxia 21% O2 and Hyperoxia 85% O2 after 6 hours and 24 hours

Project description:In this study the microRNA expression of primary murine (C57BL/6) lung alveolar type II cells belonging to four different conditions was analyzed. Effects of hyperoxia 24 hours group were compared to the normoxia 24 hours and effects of the hyperoxia 6 hours group were compared to the normoxia 6 hours.

2017-12-16 | GSE92551 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data